{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:14:12Z","timestamp":1791486852099,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["FF-026\/2566"],"award-info":[{"award-number":["FF-026\/2566"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","award":["R016737004"],"award-info":[{"award-number":["R016737004"]}],"id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","award":["R016634006"],"award-info":[{"award-number":["R016634006"]}],"id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N34E670096"],"award-info":[{"award-number":["N34E670096"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.intimp.2026.116295","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T01:12:15Z","timestamp":1770945135000},"page":"116295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["CD138-targeted bispecific protein engager-armed T cells exhibit potent and selective cytotoxicity against multiple myeloma cells"],"prefix":"10.1016","volume":"174","author":[{"given":"Pucharee","family":"Songprakhon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6160-1967","authenticated-orcid":false,"given":"Piriya","family":"Luangwattananun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornkan","family":"Choomee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunghathai","family":"Sawasdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalermchai","family":"Somboonpatarakun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaweesak","family":"Chieochansin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanya","family":"Sukpanichnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-5927","authenticated-orcid":false,"given":"Pa-Thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.116295_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/ph9010003","article-title":"The role of immunotherapy in multiple myeloma","volume":"9","author":"Kocoglu","year":"2016","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.intimp.2026.116295_bb0010","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"\u201cmultiple myeloma: 2020 update on diagnosis, risk-stratification and management,\u201d (in eng)","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116295_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/life14040461","article-title":"Role of Immune Cells and Immunotherapy in Multiple Myeloma","volume":"14","author":"Radhakrishnan","year":"2026","journal-title":"Life"},{"issue":"2","key":"10.1016\/j.intimp.2026.116295_bb0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"\u201cmanagement of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond,\u201d (in eng)","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.intimp.2026.116295_bb0025","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"\u201cmultiple myeloma: 2024 update on diagnosis, risk-stratification, and management,\u201d (in eng)","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2026.116295_bb0030","article-title":"Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo","volume":"16, no. 734","author":"D\u00edez-Alonso","year":"2024","journal-title":"(in eng), Sci Transl Med"},{"issue":"1","key":"10.1016\/j.intimp.2026.116295_bb0035","doi-asserted-by":"crossref","first-page":"2444701","DOI":"10.1080\/2162402X.2024.2444701","article-title":"\"dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers,\" (in eng)","volume":"14","author":"Velasco-Sidro","year":"2025","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2026.116295_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2024.104265","article-title":"Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: where do we stand today?","volume":"54","author":"Zhou","year":"2025","journal-title":"Presse Med."},{"issue":"5","key":"10.1016\/j.intimp.2026.116295_bb0045","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116295_bb0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-025-01675-5","article-title":"BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting","volume":"18","author":"Zheng","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116295_bb0055","first-page":"1259","article-title":"\"B-cell maturation antigen\/CD19 dual-targeting immunotherapy in newly diagnosed multiple myeloma,\" (in eng), JAMA","volume":"10","author":"Qiang","year":"2024","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2026.116295_bb0060","first-page":"24","article-title":"\"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review,\" blood","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Cancer J."},{"issue":"9","key":"10.1016\/j.intimp.2026.116295_bb0065","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.116295_bb0070","article-title":"\"therapeutic strategies to enhance immune response induced by multiple myeloma cells,\" Frontiers in immunology","volume":"14","author":"Liu","year":"2023","journal-title":"Review vol."},{"key":"10.1016\/j.intimp.2026.116295_bb0075","series-title":"\"Multiple Myeloma: Heterogeneous in Every Way,\" (in eng), Cancers (Basel)","volume":"13, no. 6","author":"Schavgoulidze","year":"2021"},{"key":"10.1016\/j.intimp.2026.116295_bb0080","doi-asserted-by":"crossref","first-page":"1370854","DOI":"10.3389\/fonc.2024.1370854","article-title":"\"targeted therapy for multiple myeloma: an overview on CD138-based strategies,\" (in eng)","volume":"14","author":"Riccardi","year":"2024","journal-title":"Front. Oncol."},{"issue":"24","key":"10.1016\/j.intimp.2026.116295_bb0085","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"(in eng), Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2026.116295_bb0090","first-page":"28","article-title":"\"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma,\" journal of cellular","volume":"2","author":"Guo","year":"2016","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.intimp.2026.116295_bb0095","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00277-017-3029-3","article-title":"\"anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement,\" (in eng)","volume":"96","author":"Tian","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2026.116295_bb0100","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"no. 43","author":"Cliff","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"1","key":"10.1016\/j.intimp.2026.116295_bb0105","first-page":"158","article-title":"\u201cbispecific antibodies in the treatment of multiple myeloma,\u201d blood","volume":"14","author":"Devasia","year":"2024","journal-title":"Cancer J."},{"key":"10.1016\/j.intimp.2026.116295_bb0110","series-title":"\"T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies,\" (in eng), Cancers (Basel)","volume":"16, no. 8","author":"Cech","year":"2024"},{"key":"10.1016\/j.intimp.2026.116295_bb0115","first-page":"2815","article-title":"Generation of a half-life extended anti-CD19 BiTE\u00ae antibody construct compatible with once-weekly dosing for treatment of CD19-positive malignancies","volume":"130","author":"Lorenczewski","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116295_bb0120","doi-asserted-by":"crossref","first-page":"1032775","DOI":"10.3389\/fonc.2022.1032775","article-title":"\u201cbispecific antibodies in multiple myeloma treatment: a journey in progress,\u201d (in eng)","volume":"12","author":"Cho","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116295_bb0125","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/08923973.2016.1153110","article-title":"\u201canti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization,\u201d (in eng)","volume":"38","author":"Chen","year":"2016","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116295_bb0130","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/cas.12631","article-title":"\u201cimmunotherapy based on bispecific T-cell engager with hIgG1 fc sequence as a new therapeutic strategy in multiple myeloma,\u201d (in eng)","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.intimp.2026.116295_bb0135","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2005-05-2177","article-title":"\u201ca novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo,\u201d (in eng)","volume":"107","author":"von Strandmann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116295_bb0140","first-page":"1","article-title":"\u201cT-cell engagers in multiple myeloma: a clinical review,\u201d (in eng)","volume":"15","author":"Al-Jarrad","year":"2025","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.intimp.2026.116295_bb0145","article-title":"Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question","author":"Ord\u00f3\u00f1ez-Reyes","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2026.116295_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111012","article-title":"Anti-PD-L1 \u00d7 anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1","volume":"124","author":"Luangwattananun","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116295_bb0155","series-title":"\"Bispecific T cell engager-armed T cells targeting integrin \u03b1\u03bd\u03b26 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma,\" (in eng), no. 1950\u20136007 (Electronic)","author":"Suwanchiwasiri","year":"2026"},{"issue":"Pt 2","key":"10.1016\/j.intimp.2026.116295_bb0160","article-title":"\u201cenhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells,\u201d (in eng)","volume":"143","author":"Supimon","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116295_bb0165","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10238-024-01347-7","article-title":"\"therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma,\" (in eng)","volume":"24","author":"Rujirachaivej","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"8016","key":"10.1016\/j.intimp.2026.116295_bb0170","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116295_bb0175","series-title":"\u201cBispecific Antibodies in Hematological Malignancies: A Scoping Review,\u201d (in eng), Cancers (Basel), vol. 15, no. 18, Sep 14","author":"Omer","year":"2023"},{"key":"10.1016\/j.intimp.2026.116295_bb0180","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"41, no. 16_suppl","author":"Lee","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116295_bb0185","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/modpathol.3880435","article-title":"Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed Syndecan-1 accumulates in fibrotic regions","volume":"14","author":"Bayer-Garner","year":"2001","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.intimp.2026.116295_bb0190","doi-asserted-by":"crossref","unstructured":"S. Z. Al-Quran, L. Yang, J. M. Magill, R. C. Braylan, and V. K. Douglas-Nikitin, \"Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry,\" Hum. Pathol., vol. 38, no. 12, pp. 1779\u20131787, 2007\/12.","DOI":"10.1016\/j.humpath.2007.04.010"},{"issue":"1","key":"10.1016\/j.intimp.2026.116295_bb0195","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202254969","article-title":"Time required for commitment to T cell proliferation depends on TCR affinity and cytokine response","volume":"24","author":"Wu","year":"2023","journal-title":"EMBO Rep."},{"key":"10.1016\/j.intimp.2026.116295_bb0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"Ellerman","year":"2019","journal-title":"Methods"},{"issue":"1","key":"10.1016\/j.intimp.2026.116295_bb0205","doi-asserted-by":"crossref","first-page":"20853","DOI":"10.1038\/s41598-023-47115-7","article-title":"Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma","volume":"13","author":"Awuah","year":"2023","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2026.116295_bb0210","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3892\/ijo.2012.1545","article-title":"\u201cmultiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide,\u201d (in eng)","volume":"41","author":"Kawano","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116295_bb0215","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s12276-024-01301-3","article-title":"Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends","volume":"56","author":"Im","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2026.116295_bb0220","series-title":"\u201cModulating T Cell Responses by Targeting CD3,\u201d (in eng), Cancers (Basel), vol. 15, no. 4","author":"Menon","year":"2023"},{"issue":"2","key":"10.1016\/j.intimp.2026.116295_bb0225","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.intimp.2026.116295_bb0230","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"\u201cBCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms,\u201d (in eng)","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116295_bb0235","series-title":"\u201cPromising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma,\u201d (in eng), Cancers (Basel), vol. 13, no. 23, Dec 6","author":"Cho","year":"2021"},{"issue":"2","key":"10.1016\/j.intimp.2026.116295_bb0240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen Yael","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2026.116295_bb0245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-141187","article-title":"Mechanisms of resistance and determinants of response of the GPRC5D-targeting T-cell redirecting bispecific antibody JNJ-7564 in multiple myeloma","volume":"136","author":"Verkleij","year":"2020","journal-title":"Blood"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926001384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926001384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T03:46:02Z","timestamp":1772336762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926001384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"alternative-id":["S1567576926001384"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116295","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD138-targeted bispecific protein engager-armed T cells exhibit potent and selective cytotoxicity against multiple myeloma cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116295"}}